PHVS

Pharvaris N.V.

Healthcare
Biotechnology
$2.66B market cap

Forecast run · Sep 14, 2026Upside rank 713 of 3,136

Model Signal

ForecastQ Daily Probabilities

50.7%

32.3%

22.5%

Analyst Consensus

Recommendation2.07/5 Buy

Last price$38.02

Price target$60.36

Implied move+58.8%

Analysts14

ForecastQ Portfolios

PHVS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.